explore -WSS

explore

author：comprehensive 2025-10-02 00:43:00 - browse：7

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Solving academic medical centers' existential crisis

knowledge

WSS

It was time to plan for my old age. If only I could stop crying

Failure, not just success, should guide future doctors

Failure, not just success, should guide future doctors

When prostate cancer spreads, where it goes matters

Restaurant meals are packed with calories, and we still keep eating them

NVIDIA and Google execs on the future of AI and drug discovery

focus

explore

hotspot

Psychedelics group wrestles with new pharma identity

Addiction experts warn against a second 'war on drugs'

Malaria cases in Florida and Texas: Here’s what you need to know

'Brian's Song' at 50 still offers lessons about cancer for today

Virginia high school admissions case could be legal follow

Sweden knocks USA out of World Cup in penalty kicks

The cancer drug shortage isn’t new — and neither are the solutions

Kansas bar where gunfire wounded 9 last month closes permanently

Psychedelics group wrestles with new pharma identity

Venture capitalist Bob Kocher on the state of digital health

hotspot

Feed a cold, starve a fever? Here’s what science says

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Sweden knocks USA out of World Cup in penalty kicks

focus

knowledge

hotspot

hotspot